BioCentury | Oct 5, 2018
Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
BioCentury | Oct 1, 2018
Financial News

New IPO filings include NGM, Arog, Gamida

Three more biotechs filed late Friday to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
BioCentury | Oct 31, 2016
Financial News

Financial tracks

...5AM Ventures named Rebecca Lucia CFO and Joe Victor venture partner. Lucia was CFO at Prospect Venture Partners...
BioCentury | Apr 21, 2014
Financial News

Nora Therapeutics completes venture financing

...Genitourinary Date completed: 4/17/14 Type: Venture financing Raised: $18 million Investors: Novo A/S ; Burrill; Prospect Venture Partners...
BioCentury | Apr 18, 2014
Financial News

Fertility play Nora raises $18 million in series B

...million in a series B round led by new investor Novo A/S. Existing investors Burrill; Prospect Venture Partners...
BioCentury | Mar 24, 2014
Financial News

NinePoint completes venture financing

...Date completed: 3/20/14 Type: Venture financing Raised: $34 million Investors: Corning Inc.; Third Rock Ventures; Prospect Venture Partners WIR...
BioCentury | Mar 20, 2014
Financial News

NinePoint raises $34 million in series B

...for high-tech applications in life sciences and other industries. Existing investors Third Rock Ventures and Prospect Venture Partners...
BioCentury | Mar 10, 2014
Finance

Innovator capital rationing

...High throughput discovery platform for developing biologics to treat cardiometabolic diseases $101 Series B, C Prospect Venture Partners...
BioCentury | Jul 22, 2013
Financial News

NGM Biopharmaceuticals completes venture financing

...Date completed: 7/18/13 Type: Venture financing Raised: $50 million Investors: Topspin Fund; The Column Group; Prospect Venture Partners...
BioCentury | Jul 19, 2013
Financial News

NGM raises $50 million in series C

...a series C round from new investor Topspin Fund and existing investors The Column Group; Prospect Venture Partners...
Items per page:
1 - 10 of 173
BioCentury | Oct 5, 2018
Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
BioCentury | Oct 1, 2018
Financial News

New IPO filings include NGM, Arog, Gamida

Three more biotechs filed late Friday to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
BioCentury | Oct 31, 2016
Financial News

Financial tracks

...5AM Ventures named Rebecca Lucia CFO and Joe Victor venture partner. Lucia was CFO at Prospect Venture Partners...
BioCentury | Apr 21, 2014
Financial News

Nora Therapeutics completes venture financing

...Genitourinary Date completed: 4/17/14 Type: Venture financing Raised: $18 million Investors: Novo A/S ; Burrill; Prospect Venture Partners...
BioCentury | Apr 18, 2014
Financial News

Fertility play Nora raises $18 million in series B

...million in a series B round led by new investor Novo A/S. Existing investors Burrill; Prospect Venture Partners...
BioCentury | Mar 24, 2014
Financial News

NinePoint completes venture financing

...Date completed: 3/20/14 Type: Venture financing Raised: $34 million Investors: Corning Inc.; Third Rock Ventures; Prospect Venture Partners WIR...
BioCentury | Mar 20, 2014
Financial News

NinePoint raises $34 million in series B

...for high-tech applications in life sciences and other industries. Existing investors Third Rock Ventures and Prospect Venture Partners...
BioCentury | Mar 10, 2014
Finance

Innovator capital rationing

...High throughput discovery platform for developing biologics to treat cardiometabolic diseases $101 Series B, C Prospect Venture Partners...
BioCentury | Jul 22, 2013
Financial News

NGM Biopharmaceuticals completes venture financing

...Date completed: 7/18/13 Type: Venture financing Raised: $50 million Investors: Topspin Fund; The Column Group; Prospect Venture Partners...
BioCentury | Jul 19, 2013
Financial News

NGM raises $50 million in series C

...a series C round from new investor Topspin Fund and existing investors The Column Group; Prospect Venture Partners...
Items per page:
1 - 10 of 173